A Covid-19 antibody treatment from Vir Biotechnology Inc. and GlaxoSmithKline Plc lost its U.S. authorization as the therapy is unlikely to work against the dominant omicron BA.2 subvariant, regulators said.
The treatment, sotrovimab, is no longer authorized in any U.S. state or territory, since the subvariant accounts for more than half of virus cases in all regions, the U.S. Food and Drug Administration said in a statement late Tuesday. Last month, the agency limited use of the drug only in parts of the country where the the subvariant dominated. Recent data suggested the treatment was less effective against BA.2 than other variants.
